Lederle’s Minocin
Executive Summary
Pelletized version of the antibiotic, approved on May 31, will replace Minocin brand of minocycline HCl tablets and capsules currently on the market. The NDA for the pelletized product presumably entitles the company to exclusivity under Waxman/Hatch. Minocin, Lederle's largest selling product with sales "in excess of $100 mil.," is off-patent but currently not subject to generic competition. However, the Italian company Biochimica Opos obtained the first ANDA approval for minocycline (in nonsterile bulk) on May 31.
You may also be interested in...
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.